We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cancer Trial Underreporting Blamed on Time Constraints, Investigator Relocation
Cancer Trial Underreporting Blamed on Time Constraints, Investigator Relocation
September 19, 2005
Phase I cancer drug trials conducted to determine the safety and maximum dosage of a new agent are underreported in peer-reviewed journals — a trend that may delay scientific advances and harm patient care — say researchers at The University of Texas M. D. Anderson Cancer Center (ACC) in a new study recently published in the journal Cancer.